Degenerative Lesion of Articular Cartilage of Knee Clinical Trial
Official title:
Randomized Controlled Trial of Microfracture Versus Adipose Derived Stem Cells for the Treatment of Isolated Articular Cartilage Defects
The purpose of this study is to compare two biologic methods for the treatment of articular cartilage defects in the knee. The first method, microfracture, is the standard of care and is routinely used to recruit cells from the subchondral bone marrow to the site of cartilage loss. The second method is the application of adipose-derived stem cells (ADSCs) to the defect site. In theory, ADSCs on a collagen scaffold should enable the delivery of more specific progenitor cells to the site of injury, resulting in better regeneration and integration of articular cartilage at the site of a defect as compared to the microfracture method.
Patients enrolled in the ADSC cohort will undergo the following procedures: arthroscopic resection of approximately 5cc of the infrapatellar fat pad using a motorized shaver (standard use in arthroscopy). Fat will be collected in a sterile Aquavage Collection System (AV1200, MD Resources, Livermore, CA) and kept sealed until processing. Fat will then immediately be processed in the Harvest Adiprep System to separate a population of ADSCs. This system concentrates an average of 5 x 105 cells/ml. All specimens will be processed using routine sterile procedures within the operating room; cells destined for implantation will not leave the operating room. Concurrently, patients will undergo arthroscopy and similar preparation of the chondral defect and removal of the calcified cartilage layer. However, no puncture of the subchondral bone will be performed. A layer of fibrin glue (Tisseel) will be placed at the base of the defect to seal off any bleeding from the subchondral plate followed by the application of the acellular dermal matrix (Allopatch HD, MTF Corporation, Edison, NJ, USA)and ADSCs. An additional layer of Tisseel will then be applied over the cells and matrix. No additional fixation will be applied. The matrix and cells will be recessed below the articular surface by an average of 1mm. They will then complete outcome questionnaires and additional MRI scans at 6, 12, and 24 months post-operatively. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02345564 -
Clinical and Radiological Results of Osteochondral Repair Using MaioRegen in Knee and Ankle Surgery
|
N/A | |
| Completed |
NCT02285725 -
Microdrilling Surgery for Full Thickness Chondral Lesions of the Knee Augmented With Concentrated Bone Marrow Aspirate, Platelet Rich Plasma and Hyaluronic Acid
|
N/A | |
| Recruiting |
NCT04000659 -
Episealer® Knee System IDE Clinical Study
|
N/A | |
| Terminated |
NCT02981355 -
Randomized Evaluation of BST-CarGel Versus Microfracture Alone On Recovery From Distal Femoral Cartilage Lesions
|
Phase 4 | |
| Completed |
NCT01554878 -
Observational Study on the Treatment of Knee Osteochondral Lesions of Grade III-IV
|
N/A | |
| Completed |
NCT01576159 -
Serum Cartilage Oligomeric Matrix Protein Levels After 12 Weeks of Different Exercises
|
Phase 0 | |
| Active, not recruiting |
NCT01329445 -
DeNovo NT Longitudinal Data Collection (LDC) Knee Study
|
N/A | |
| Completed |
NCT01605201 -
Tissue Engineered Nasal Cartilage for Regeneration of Articular Cartilage
|
Phase 1 |